期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
麦考酚酸酯治疗AQP4抗体阳性视神经炎疗效观察 被引量:1
1
作者 曾峥 杨淑芳 +4 位作者 刘晓瑞 杨春生 孙立新 王甜 由彩云 《国际眼科杂志》 CAS 北大核心 2022年第6期887-891,共5页
目的:评价麦考酚酸酯(MMF)对AQP4抗体阳性视神经脊髓炎谱系障碍(NMOSD)患者预防复发和视力预后的作用。方法:回顾性病例研究。收集2017-01/2019-12收治的AQP4抗体阳性NMOSD患者11例,其中男3例,女8例。NMOSD特有的重要临床表现为视神经... 目的:评价麦考酚酸酯(MMF)对AQP4抗体阳性视神经脊髓炎谱系障碍(NMOSD)患者预防复发和视力预后的作用。方法:回顾性病例研究。收集2017-01/2019-12收治的AQP4抗体阳性NMOSD患者11例,其中男3例,女8例。NMOSD特有的重要临床表现为视神经炎。发病平均年龄36.3±6.0(27~47)岁,平均病程3.4±1.4(2.2~6.8)a。在NMOSD缓解期加用MMF 1a或1a以上。记录应用MMF患者的年复发率(ARR)、最佳矫正视力(BCVA)和不良反应。结果:MMF治疗的中位时间为18(12,36)mo。ARR在基线时为0.66/a,治疗后为0.16/a。91%的患者ARR下降,82%的患者无临床复发。MMF治疗后ARR明显改善(P<0.05)。治疗后平均BCVA与治疗前比较无显著差异(P>0.05)。11例患者中,3例(27%)出现不良反应,其中1例(9%)出现转氨酶升高,2例(18%)出现轻度胃肠道反应。没有因不良反应而停用MMF的情况。结论:MMF治疗AQP4抗体阳性NMOSD患者能在一定程度上降低其视神经炎的ARR,保护患者的视功能。 展开更多
关键词 视神经脊髓炎谱系障碍 视神经炎 麦考酚酸酯 复发 视力
下载PDF
Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis 被引量:4
2
作者 Qi-Guang Shi Zhi-Hong Wang +4 位作者 Xiao-Wei Ma Da-Qi Zhang chun-sheng yang Fu-Dong Shi Li yang 《Neuroscience Bulletin》 SCIE CAS CSCD 2012年第5期469-474,共6页
Objective To evaluate the frequency, distribution and clinical significance of the antibodies to the fetal and/or adult acetylcholine receptor (AChR) in patients with myasthenia gravis (MG). Methods AChR antibodie... Objective To evaluate the frequency, distribution and clinical significance of the antibodies to the fetal and/or adult acetylcholine receptor (AChR) in patients with myasthenia gravis (MG). Methods AChR antibodies were detected by cell-based assay in the serum of ocular MG (OMG) (n = 90) and generalized MG (GMG) patients (n = 110). The fetal-type (2α: β: γ: δ) and adult-type (2α: β: ε: δ) AChR were used as antigens, and their relevance to disease presentation was assessed. Results The overall frequencies of anti-adult and anti-fetal AChR antibodies were similar in all 200 patients examined, with 14 having serum specific to the AChR-γ subunit, and 22 to the AChR-ε subunit. The overall sensitivity when using the fetal and adult AChR antibodies was higher than that when using the fetal AChR antibody only (P = 0.015). Compared with OMG patients, the mean age at disease onset and the positive ratio of antibodies to both isoforms of the AChR were significantly higher in patients who subsequently progressed to GMG. Older patients and patients with both anti-fetal and anti-adult AChR antibodies had a greater risk for developing generalized disease [odds ratio (OR), 1.03; 95% confidence interval (CI), 1.01–1.06 and OR, 5.09; 95% CI, 2.23–11.62]. Conclusion Using both fetal-and adult-type AChRs as the antigens may be more sensitive than using either subtype. Patients with serum specific to both isoforms are at a greater risk of progressing to GMG. Patients with disease onset at an advanced age appear to have a higher frequency of GMG conversion. 展开更多
关键词 myasthenia gravis acetylcholine receptor antibodies acetylcholine receptor subunit cell-based assay adult fetal
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部